Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Monjuvi (tafasitamab-cxix) is a CD19-directed monoclonal antibody that targets and depletes CD19-expressing B-cells. Monjuvi is the US brand name; the same active ingredient is marketed outside the United States as Minjuvi.
Monjuvi, combined with lenalidomide, is FDA-approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplant. In June 2025, the FDA additionally approved Monjuvi combined with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
Tafasitamab binds to CD19 on the surface of B-cells and mediates cell lysis through antibody-dependent cellular cytotoxicity and phagocytosis, working synergistically with lenalidomide's immunomodulatory effects.
The recommended dose is 12 mg/kg administered as an intravenous infusion, combined with lenalidomide (and rituximab, for the follicular lymphoma indication) for up to 12 cycles, as determined by the treating hematologist-oncologist.
Monjuvi requires close monitoring for several serious adverse effects, particularly during the initial infusion cycles.
Can occur, particularly during the first infusion. Monitor closely and manage with infusion interruption or premedication as needed.
Neutropenia, thrombocytopenia, and anemia are common. Monitor complete blood counts regularly, especially during the first cycles.
Serious infections, including opportunistic infections, have been reported. Monitor for signs of infection throughout treatment.
Monjuvi combined with lenalidomide can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose. Lenalidomide itself carries additional pregnancy-related restrictions (REMS program).
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Monjuvi (tafasitamab-cxix) is marketed by Incyte Corporation, which holds exclusive global rights to tafasitamab. Monjuvi is the US brand name; the same active ingredient is marketed outside the US as Minjuvi.
Import of Monjuvi through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of DLBCL or follicular lymphoma diagnosis, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Monjuvi directly from Incyte's authorized supply chain to ensure product authenticity and regulatory compliance.
Monjuvi is sourced through verified, GDP-compliant, cold-chain channels from Incyte's authorized supply chain to ensure authenticity and quality.
Monjuvi should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Monjuvi is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Monjuvi through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support lymphoma diagnosis and treatment coordination for Monjuvi access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Monjuvi.
Bangalore's oncology network offers access to lymphoma treatment planning for eligible patients.
Chennai-based specialists coordinate Monjuvi access alongside comprehensive lymphoma care.
Hyderabad's cancer care institutions support patients pursuing Monjuvi therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Monjuvi.
Pune-based hematologists assist with diagnosis confirmation and Monjuvi treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Monjuvi.
Kochi's oncology units assist patients with the documentation needed for Monjuvi access.
Chandigarh's cancer care centers support Monjuvi treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Monjuvi access process.
Lucknow-based cancer centers assist patients pursuing Monjuvi therapy.
Bhubaneswar's oncology institutions support access to Monjuvi for eligible patients.
Guwahati's specialists help coordinate Monjuvi access for patients across the Northeast.
Patients in other cities across India can also access Monjuvi through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
